H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been acknowledged with the 2019 Lasker-DeBakey Clinical Medical Research Award
A member of PLC’s () scientific advisory board has received the American scientific equivalent to the Nobel Prize.
H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been recognised with the 2019 Lasker-DeBakey Clinical Medical Research Award.
The Lasker Foundation said that Shepard's research "executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life”.
Hemogenyx chief executive Vladislav Sandler said: "We are thrilled that Dr Shepard's life-saving work has been recognised by this prestigious award and we are fortunate to have such a distinguished scientist advising our own organisation's cutting-edge cancer research."
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE